Clinical Trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Hungary

Total 156 results

argenx

Completed

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Octapharma

Completed

Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy (CIDP)

Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

Canada, Poland, Romania, Ukraine, Bulgaria, Czechia, Germany, Hungary, Russian Federation
Somogy Megyei Kaposi Mór Teaching Hospital

Completed

Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients

Multiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Primary Progressive

Hungary
Somogy Megyei Kaposi Mór Teaching Hospital
University Medical Center Groningen

Completed

The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients

Multiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Primary Progressive

Hungary
Lycera Corp.

Completed

Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis

Ulcerative Colitis

Hungary
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis

Ulcerative Colitis

Poland, Bulgaria, Hungary
Abivax S.A.

Active, not recruiting

Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis

Belgium, Poland, Czechia, Hungary
Sanofi

Completed

Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study (NICE)

Ulcerative Colitis | Inflammatory Bowel Disease

Canada, Brazil, Russian Federation, Italy, Spain, Sweden, Estonia, Singapore, Belgium, Czech Republic, Argentina, Hungary, Chile, South Africa
Hoffmann-La Roche

Terminated

Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)

Ulcerative Colitis

United States, Hungary, Georgia, Moldova, Republic of, Ukraine
Novo Nordisk A/S

Terminated

A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis

Inflammation | Ulcerative Colitis

Poland, Croatia, Denmark, Bulgaria, Hungary, Ukraine, Russian Federation
Protagonist Therapeutics, Inc.

Completed

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Severe

United States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
Geert D'Haens
Takeda

Completed

An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis (LOVE-UC)

Colitis, Ulcerative

Netherlands, Belgium, Hungary
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (O'HAND)

Multiple Sclerosis, Primary Progressive

Canada, United States, Spain, Croatia, Serbia, Portugal, France, Tunisia, Mexico, Poland, Russian Federation, Australia, Belgium, Italy, United Kingdom, Ukraine, Bulgaria, Colombia, Georgia, Germany, Romania, New Zealand, Lebanon, Aus... and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Multiple Sclerosis

United States, Brazil, Poland, United Kingdom, Turkey, Bulgaria, Belgium, Canada, Denmark, France, Germany, Greece, Hungary, Italy, Peru, Portugal, Russian Federation, Spain, Switzerland, Ukraine, Mexico, Argentina
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (FENtrepid)

Multiple Sclerosis, Primary Progressive

United States, Canada, Australia, United Kingdom, Hungary, Bulgaria, Puerto Rico, Poland, Argentina, Brazil, Germany, Greece, Italy, Peru, Portugal, Russian Federation, Spain, Turkey, Ukraine, Israel, France, Switzerland, Colombia, Me... and more
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Multiple Sclerosis, Primary Progressive

United States, Canada, Australia, Hungary, Brazil, Finland, Italy, Germany, Romania, Lithuania, France, Greece, Peru, Portugal, Spain, Switzerland, Bulgaria, Ukraine, Israel, Poland, Austria, New Zealand, Netherlands, Belgium, Mexico, United... and more
Sanofi

Recruiting

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) (PERSEUS)

Primary Progressive Multiple Sclerosis

Spain, Italy, Turkey, India, Israel, Bulgaria, Mexico, Greece, Portugal, United States, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, France, Georgia, Germany, Hungary, Japan and more
Novartis Pharmaceuticals

Terminated

Efficacy & Safety in Moderately Active Refractory Ulcerative Colitis Patients

Ulcerative Colitis

Belgium, Hungary, Switzerland, Germany, Sweden, United Kingdom
Palau Pharma S.A.

Completed

A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

Belgium, Hungary, Slovakia, Spain
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis (CONSONANCE)

Progressive Multiple Sclerosis (PMS)

United States, Canada, Brazil, France, Netherlands, Ireland, Germany, Italy, Poland, Russian Federation, Spain, Colombia, Morocco, Hungary, Denmark, Lebanon, Mexico, Costa Rica, Bosnia and Herzegovina, Czechia, Egypt, Guatemala, Panama and more
Eli Lilly and Company

Recruiting

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-URGE)

Ulcerative Colitis | Ulcerative Colitis Chronic

United Kingdom, United States, Poland, Czechia, Hungary, Italy, France, Slovakia, Germany, Belgium
MedDay Pharmaceuticals SA

Terminated

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) (SPI2)

Multiple Sclerosis

United States, Spain, Canada, Australia, United Kingdom, Belgium, Turkey, Czechia, Poland, Italy, Hungary, Germany, Sweden
Novartis Pharmaceuticals

Completed

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

Secondary Progressive Multiple Sclerosis

China, Germany, United States, Romania, Italy, Austria, Belgium, Czechia, Spain, Australia, Canada, France, Israel, Switzerland, Bulgaria, Hungary, Netherlands, United Kingdom, Estonia, Latvia, Lithuania, Russian Federation, Turkey, J... and more
Abivax S.A.

Completed

ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis

Spain, France, Belgium, Poland, Hungary, Austria, Czechia, Germany
Kyowa Kirin, Inc.

Completed

Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis

Digestive System Diseases | Gastrointestinal Diseases | Colonic Diseases | Intestinal Diseases | Abdominal Pain | Inflammatory Bowel Diseases | Ulcerative Colitis | Colitis | Colitis, Ulcerative | Autoimmune Disease

Hungary, Russian Federation, Serbia, United States, Poland, Czechia, Romania
Novartis Pharmaceuticals

Terminated

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. (INFORMS)

Primary Progressive Multiple Sclerosis

United States, Belgium, Poland, Germany, Hungary, Turkey, Spain, Australia, Canada, Czechia, Switzerland, United Kingdom, Netherlands, France, Italy, Denmark, Finland, Sweden
Avaxia Biologics, Incorporated

Completed

Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis

Ulcerative Colitis

United States, Hungary, Belgium, Canada
Topivert Pharma Ltd

Completed

Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis (TOP2)

Ulcerative Colitis

Poland, Ukraine, United Kingdom, Bulgaria, Hungary, Lithuania, Czechia, Latvia
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Netherlands, Canada, Hungary, Moldova, Republic of, Romania
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Australia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Belgium, Hungary, Croatia, ...
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Russian Federation, Austria, Hungary, ... and more
InDex Pharmaceuticals

Completed

The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients (COLLECT)

Colitis, Ulcerative

Czechia, France, Germany, Hungary, Italy, Poland, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Ulcerative Colitis

United States, Georgia, Germany, Hungary, Moldova, Republic of, Poland, Ukraine, United Kingdom
Galapagos NV

Completed

Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis (ORIGIN)

Ulcerative Colitis

Belgium, Czech Republic, Germany, Hungary, Poland, Russian Federation
Sanofi

Active, not recruiting

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Secondary Progressive Multiple Sclerosis

United States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more
Lycera Corp.

Terminated

Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Colitis, Ulcerative

United States, Czechia, Hungary, Netherlands, Poland, Serbia
Morphic Therapeutic, Inc

Recruiting

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC (EMERALD-2)

Inflammatory Bowel Diseases | Colitis, Ulcerative

United States, Germany, Korea, Republic of, Italy, Poland, Australia, Georgia, Austria, Bulgaria, Czechia, Estonia, France, Hungary, India, Israel, Latvia, Lithuania, Romania, Serbia, Slovakia, Taiwan
Celgene

Completed

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

Colitis, Ulcerative

United States, Canada, Slovakia, Poland, Bulgaria, Hungary
Amgen

Recruiting

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Germany, Japan, Denmark, Romania, Argentina, Bulgaria, Hungary, Korea, Republic of, Mexico, Poland, Switzerland, Turkey
Celgene

Active, not recruiting

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Germany, Greece, United Kingdom, Hungary, Belgium, Slovakia, Bulgaria, Italy, Australia, Israel, Belarus, Romania, Ukraine
Shire

Completed

Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis (PACE)

Ulcerative Colitis

United States, United Kingdom, Israel, Canada, Hungary, Poland, Slovakia
OSE Immunotherapeutics

Recruiting

Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis (CoTikiS)

Ulcerative Colitis

Belgium, Latvia, Bulgaria, Belarus, Croatia, Georgia, Hungary, Poland, Russian Federation, South Africa, Ukraine
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UNIFI)

Inflammatory Bowel Diseases | Colitis, Ulcerative

United States, Australia, France, Poland, Ukraine, United Kingdom, Belgium, Germany, Israel, Bulgaria, Romania, Serbia, Japan, Canada, Netherlands, Korea, Republic of, New Zealand, Russian Federation, Austria, Hungary, Slovakia, D... and more
Facet Biotech
PDL BioPharma, Inc.

Terminated

Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study

Ulcerative Colitis

Belgium, France, United States, Italy, Canada, Czech Republic, Norway, Israel, Austria, Croatia, Australia, Hungary, Ukraine, Netherlands, Germany
sigma-tau i.f.r. S.p.A.
PRA Health Sciences

Terminated

Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study

Ulcerative Colitis

Poland, Hungary, Austria, France, Germany, Latvia, Lithuania, Spain
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Colitis, Ulcerative

France, Ukraine, United States, Poland, Bulgaria, Canada, Netherlands, Belgium, Russian Federation, Germany, Hungary, Czech Republic
Genentech, Inc.

Completed

Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Israel, Belgium, Australia, Czechia, New Zealand, Canada, Spain, Germany, United Kingdom, Hungary
Janssen Research & Development, LLC

Active, not recruiting

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC) (UNIFI Jr)

Colitis, Ulcerative

United States, Israel, Belgium, Hungary, Japan, Germany, Poland, United Kingdom, Russian Federation
Ferring Pharmaceuticals

Completed

Study to Assess Effectiveness of Therapy Timely Adjustment Based on Self-monitoring in Patients Suffering From Mild-to-moderate Ulcerative Colitis (OPTIMISE Study) (OPTIMISE)

Mild-to-moderate Ulcerative Colitis

Poland, Hungary, Italy, Czechia, Netherlands, Slovakia
Bristol-Myers Squibb

Completed

A Study of MDX-1100 in Subjects With Active Ulcerative Colitis (MDX1100-06)

Ulcerative Colitis

Ukraine, United States, Romania, Russian Federation, Czech Republic, Hungary, Canada, Latvia

Clinical Trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Hungary

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations